Atrial Fibrillation Prevalence With Mavacamten for Obstructive Hypertrophic Cardiomyopathy

被引：0
|
作者：
Jaikumar, Likhitesh
Biswas, Monodeep
Kagan, Calvin
Amara, Richard S.
Reck, Kim M.
Shorofsky, Stephen
Dickfeld, Timm
Wang, Libin
See, Vincent Y.
机构：
来源：
CIRCULATION | 2023年 / 148卷
关键词：
Hypertrophic cardiomyopathy; Atrial fibrillation; Drugs; Graft patency;
D O I：
10.1161/circ.148.suppl_1.19176
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A19176
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with Mavacamten
    Castrichini, Matteo
    Alsidawi, Said
    Geske, Jeffrey B.
    Newman, Darrell B.
    Arruda-Olson, Adelaide M.
    Bos, J. Martijn
    Ommen, Steve R.
    Siontis, Konstantinos C.
    Ackerman, Michael J.
    Giudicessi, John R.
    HEART RHYTHM, 2024, 21 (10) : 2065 - 2067
  • [2] Mavacamten for hypertrophic obstructive cardiomyopathy
    Quintana, Eduard
    Bajona, Pietro
    Myers, Patrick O.
    LANCET, 2021, 397 (10272): : 369 - 369
  • [3] Atrial fibrillation in hypertrophic obstructive cardiomyopathy: prevalence, symptoms and quality of live
    Obergassel, L
    Lawrenz, T
    Gietzen, FH
    Strunk, C
    EUROPEAN HEART JOURNAL, 2002, 23 : 487 - 487
  • [4] Mavacamten for Obstructive Hypertrophic Cardiomyopathy in China
    Desai, Milind Y.
    JAMA CARDIOLOGY, 2023, 8 (10) : 966 - 967
  • [5] Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2022, 64 (1652): : 89 - 91
  • [6] Atrial Fibrillation in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy Real-World Incidence, Management, and Outcomes
    Boyle, Thomas A.
    Reza, Nosheen
    Hyman, Matthew
    Supple, Gregory
    See, Vincent Y.
    Marzolf, Amy
    Hornsby, Nicole
    de Feria, Alejandro
    Wang, Teresa
    Margulies, Kenneth B.
    Owens, Anjali Tiku
    Frankel, David S.
    JACC-CLINICAL ELECTROPHYSIOLOGY, 2024, 11 (02) : 411 - 413
  • [7] Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy
    Rader, Florian
    Oreziak, Artur
    Choudhury, Lubna
    Saberi, Sara
    Fermin, David
    Wheeler, Matthew T.
    Abraham, Theodore P.
    Garcia-Pavia, Pablo
    Zwas, Donna R.
    Masri, Ahmad
    Owens, Anjali
    Hegde, Sheila M.
    Seidler, Tim
    Fox, Shawna
    Balaratnam, Ganesh
    Sehnert, Amy J.
    Olivotto, Iacopo
    JACC-HEART FAILURE, 2024, 12 (01) : 164 - 177
  • [8] Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension
    Wang, Andrew
    Spertus, John A.
    Wojdyla, Daniel M.
    Abraham, Theodore P.
    Nilles, Ester Kim
    Owens, Anjali Tiku
    Saberi, Sara
    Cresci, Sharon
    Sehnert, Amy
    Lakdawala, Neal K.
    JACC-HEART FAILURE, 2024, 12 (03) : 567 - 579
  • [9] MAVACAMTEN USE FOR OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY IN AN OCTOGENARIAN
    Chandrasekhar, Sanjay Amrith
    Enciso, Juan
    Casals, Luke R.
    Wu, Robby
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 2801 - 2801
  • [10] Incidence and recurrence of atrial fibrillation among patients with obstructive hypertrophic cardiomyopathy treated with mavacamten: a single-center experience
    Liang, Lusha W.
    Lumish, Heidi S.
    Shimada, Yuichi J.
    Weiner, Shepard D.
    CLINICAL RESEARCH IN CARDIOLOGY, 2024,
12345